Table 2. Summary of identified age-stratified clinical VL incidence studies.
Study | Location | Date | Study Population | Total VL Cases | Clinical VL Incidence (per 1000 people/yr) | Serological Test | |||
---|---|---|---|---|---|---|---|---|---|
From | To | rK39 RDT | rK39 ELISA | DAT | |||||
Barnett et al, 2005 [59] | Uttar Pradesh, India | 1999 | 2004 | 2203 | 43 | 6.5 | ✓ | ||
Bern et al, 2005 [25] | Bangladesh | 01/1999 | 06/2004 | 2507* | 182* | 13.20 | ✓ | ✓ | |
Ferdousi et al, 2010 [60] | Bangladesh | 08/2006 | 08/2008 | 6955 | 248 | 12.23 | ✓ | ||
Hasker et al, 2012 [61] | Bihar, India | 09/2008 | 10/2010 | 81210 | 207 | 0.73 | ✓ | ||
Hasker et al, 2013 [23] | Bihar, India | 03/2007 | 12/2009 | 19886 | 115 | 3.17 | ✓ | ✓ | |
Picado et al, 2014 [62] | India + Nepal | 11/2006 | 05/2009 | 17610 | 95 | 2.16 | ✓ | ✓ | |
Singh et al, 2010a [63]** | Bihar, India | 01/2006 | 12/2006 | 31324 | 177 | 5.7 |
* Figures taken from Chapman et al (2015) [2].
** Information on serological testing performed for Singh et al, 2010a not available